Attovia discloses Vida Ventures’ preferred stake
Attovia Therapeutics, Inc. reports initial insider ownership by Vida Ventures funds through holdings of Series C Preferred Stock, which is convertible into Common Stock on a 9.29-for-1 basis with no expiration date.
Rhea-AI Filing Summary
Attovia Therapeutics, Inc. reports initial insider ownership by Vida Ventures funds through holdings of Series C Preferred Stock, which is convertible into Common Stock on a 9.29-for-1 basis with no expiration date. Upon the closing of an initial public offering of Common Stock, all Series C Preferred shares will automatically convert into Common Stock on the same 9.29-for-1 basis without additional consideration. Vida Ventures III, L.P. holds indirect interests in 937,265 underlying Common shares, and Vida Ventures III-A, L.P. holds indirect interests in 2,160 underlying Common shares. The general partner and its investment committee members may be deemed to share voting and investment power but disclaim beneficial ownership beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Vida Ventures GP III, L.L.C., Vida Ventures III, L.P., Vida Ventures III-A, L.P.
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series C Preferred Stock F1, F2, F3 | -- | -- | -- |
| holding | Series C Preferred Stock F1, F4 | -- | -- | -- |
Holdings After Transaction:
Series C Preferred Stock — 937,265 contracts (Indirect, By Vida Ventures III, L.P.);
Series C Preferred Stock — 2,160 contracts (Indirect, By Vida Ventures III-A, L.P.)
Footnotes (4)
- F1. Each share of Series C Preferred Stock is convertible into shares of the Issuer's Common Stock on a 9.29-for-1 basis and has no expiration date. All shares of Series C Preferred Stock will automatically convert on a 9.29-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
- F2. These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim, and Rajul Jain are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").
- F3. (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment, and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
- F4. These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment, and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Key Figures
Underlying Common Shares (Vida Ventures III, L.P.): 937,265 shares
Underlying Common Shares (Vida Ventures III-A, L.P.): 2,160 shares
Conversion Ratio: 9.29-for-1
3 metrics
Underlying Common Shares (Vida Ventures III, L.P.)
937,265 shares
Indirectly issuable upon conversion of Series C Preferred Stock
Underlying Common Shares (Vida Ventures III-A, L.P.)
2,160 shares
Indirectly issuable upon conversion of Series C Preferred Stock
Conversion Ratio
9.29-for-1
Each Series C Preferred share convertible into Common Stock on this basis
Key Terms
Series C Preferred Stock, initial public offering, pecuniary interest, disclaims beneficial ownership
4 terms
Series C Preferred Stock financial
"Each share of Series C Preferred Stock is convertible into shares of the Issuer's Common Stock"
A Series C preferred stock is a specific class of ownership issued during a later funding round that gives holders priority over common shareholders for getting paid and receiving dividends, like having a reserved lane in traffic when money is distributed. It often includes agreed rights such as a fixed payout, protection against dilution, and the option to convert into common shares, so investors treat it as a mix of safety and upside potential.
initial public offering financial
"will automatically convert ... upon the closing of the Issuer's initial public offering of its Common Stock"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
pecuniary interest financial
"except to the extent of their pecuniary interest therein, if any"
disclaims beneficial ownership financial
"disclaims beneficial ownership of the securities held of record by Vida III"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider ownership does the Form 3 for ATTO disclose for Vida Ventures?
The Form 3 shows Vida Ventures-affiliated funds holding Series C Preferred Stock in Attovia Therapeutics, indirectly representing 937,265 and 2,160 underlying Common shares through Vida Ventures III, L.P. and Vida Ventures III-A, L.P., respectively.
How does Attovia Therapeutics (ATTO) Series C Preferred Stock convert into Common Stock?
Each share of Attovia’s Series C Preferred Stock is convertible into Common Stock on a 9.29-for-1 basis. All Series C Preferred shares will automatically convert into Common Stock on this same basis upon the closing of an initial public offering.
Are the ATTO holdings reported on the Form 3 direct or indirect for Vida Ventures?
The holdings are reported as indirect. Shares are held directly by Vida Ventures III, L.P. and Vida Ventures III-A, L.P., with the general partner and investment committee potentially sharing power but disclaiming beneficial ownership beyond any pecuniary interest.
Does the ATTO Form 3 indicate any recent buy or sell transactions by Vida Ventures?
No buy or sell transactions are reported. The Form 3 provides an initial statement of beneficial ownership, listing indirect holdings of Series C Preferred Stock rather than recording new purchases or sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
